Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 plus radiotherapy for brain metastases from solid tumors
CTR20201657Phase 2Completed
- Sponsor
- Tianjin Xinyi Shangde Biomedical Technology
- Start
- Mar 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dimethylaminomicheliolide in brain metastases, sponsored by Tianjin Xinyi Shangde Biomedical Technology. Started Mar 2021; status: completed.
02
Drugs
dimethylaminomicheliolide
03
Conditions
brain metastases
Beyond the preview
Go deeper on CTR20201657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201657.